Takeda Tests New Highs, But Struggles To Find Entyvio Successor
Source: SeekingAlpha
2026-01-30 14:10:18 ET
We last touched on Takeda Pharmaceutical Company Limited ( TAK ) back in May, at the end of the previous fiscal year. The stock was beaten down, and while we were expecting 2025 to be a challenge, I rated it a buy because it was a chance to buy exposure to global pharmaceuticals relatively cheaply, and with prospects for dividend growth. The stock stayed roughly flat for months, but started to trend upward in recent weeks, culminating with gains Thursday on their Q3 earnings release....
Read the full article on Seeking Alpha
For further details see:
Takeda Tests New Highs, But Struggles To Find Entyvio Successor
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
-0.63% G/L:
$18.115 Last:
1,281,262 Volume:
$18.15 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
